Introduction to Biomedical Nanotechnology
暂无分享,去创建一个
[1] Russell J Mumper,et al. Biotargeted nanomedicines for cancer: six tenets before you begin. , 2013, Nanomedicine.
[2] S. Barry,et al. Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[3] Robert Sinclair,et al. The Fate and Toxicity of Raman-Active Silica-Gold Nanoparticles in Mice , 2011, Science Translational Medicine.
[4] Vladimir Torchilin,et al. Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.
[5] A. Jordan,et al. Clinical applications of magnetic nanoparticles for hyperthermia , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[6] W. Zamboni,et al. Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents , 2012, Clinical pharmacology and therapeutics.
[7] Zhuang Liu,et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. , 2008, Nature nanotechnology.
[8] Molly M Stevens,et al. Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. , 2012, Nature nanotechnology.
[9] M. Christian,et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.
[10] Mauro Ferrari,et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.
[11] Marina A. Dobrovolskaia,et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[12] Mauro Ferrari,et al. An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. , 2010, Advances in genetics.
[13] C. Lieber,et al. Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species , 2001, Science.
[14] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[15] Chad A Mirkin,et al. Scanometric microRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates. , 2012, Analytical chemistry.
[16] You Han Bae,et al. Recent progress in tumor pH targeting nanotechnology. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[17] Robert Sinclair,et al. Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging. , 2011, Small.
[18] N. Svrzikapa,et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.
[19] M. Cima,et al. Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers , 2011, Nature Biotechnology.
[20] Ji-Ho Park,et al. Cooperative nanomaterial system to sensitize, target, and treat tumors , 2009, Proceedings of the National Academy of Sciences.
[21] Mary E Napier,et al. More effective nanomedicines through particle design. , 2011, Small.
[22] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[23] O. Abudayyeh,et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease , 2012, Nature Biotechnology.
[24] Jinwoo Cheon,et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.
[25] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[26] P. Jain,et al. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. , 2007, Nanomedicine.
[27] G. Robertson,et al. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems , 2012, Expert opinion on drug metabolism & toxicology.
[28] Antony Thomas,et al. The shape of things to come: importance of design in nanotechnology for drug delivery. , 2012, Therapeutic delivery.
[29] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[30] R. Müller,et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.
[31] D. Chan,et al. The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[32] Roger Y Tsien,et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. , 2009, Integrative biology : quantitative biosciences from nano to macro.
[33] Robert L White,et al. Multiplex protein assays based on real-time magnetic nanotag sensing , 2008, Proceedings of the National Academy of Sciences.
[34] R Jason Stafford,et al. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. , 2009, Cancer research.
[35] V. Muzykantov,et al. Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.
[36] C. Mirkin,et al. Scanometric DNA array detection with nanoparticle probes. , 2000, Science.
[37] Mark R Wiesner,et al. Antibacterial activity of fullerene water suspensions (nC60) is not due to ROS-mediated damage. , 2008, Nano letters.
[38] Mark E. Davis,et al. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane , 2012, Proceedings of the National Academy of Sciences.
[39] S. Nie,et al. Luminescent quantum dots for multiplexed biological detection and imaging. , 2002, Current opinion in biotechnology.
[40] Scott E McNeil,et al. Nanoparticle therapeutics: a personal perspective. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[41] Robert Langer,et al. Impact of nanotechnology on drug delivery. , 2009, ACS nano.
[42] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[43] P. Houghton,et al. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. , 2004, European journal of cancer.
[44] Neetu Singh,et al. Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.
[45] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[46] W. Zamboni,et al. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs , 2012, Journal of liposome research.
[47] N. Sadrieh,et al. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. , 2011, Methods in molecular biology.
[48] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[49] R. Duncan,et al. Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.
[50] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[51] Hakho Lee,et al. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. , 2010, Nature nanotechnology.
[52] Hakho Lee,et al. Micro-NMR for Rapid Molecular Analysis of Human Tumor Samples , 2011, Science Translational Medicine.
[53] D. Ingber,et al. Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels , 2012, Science.
[54] H. Klocker,et al. Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomy , 2009, Proceedings of the National Academy of Sciences.